Growth Hormone Treatment in Children With Hypophosphatemic Rickets

Phase 2CompletedNCT02720770

Bicetre Hospital19 enrolled

Overview

This study evaluates the effect on height of a two year treatment with growth hormone in 19 children with X linked hypophosphatemic rickets.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

X Linked Hypophosphatemic Rickets

Interventions

norditropine simplexDRUG

Eligibility

Sex: ALLMin age: 3 YearsMax age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * clinical, biochemical and genetic diagnosis of XLH * height SDS \< 2 * at least two years of treatment with oral phosphate and calcitriol Exclusion Criteria: * uncontrolled rickets (ALP\>600 IU) * growth hormone deficiency * hyperparathyroidism, nephrocalcinosis, renal insufficiency * associated disease * previous treatment with growth hormone

Outcomes

Primary Outcomes

change from baseline in height SDS (standard deviation score)

Time frame: at year one and year two from baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.